Find your next M&A target
Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.
British Biomedicine R&D firm with new drug against MRSA looking for investors
|Project region||Britain, United Kingdom|
|Total value of the target||N/A|
|Expected target net rate of return after deducting all taxes and fees||N/A|
|Validity period of pending order||365|
Senior Associate, International Business Advisory
|Project highlights||The market value is 19 million pounds.|
The company has developed a new anti-infection drug with outstanding and rapid bacterial activity against Staphylococcus aureus (SA), which is the biggest cause of nosocomial bacterial infection in the world. The leading drug has completed clinical trials funded by the US government. Different from traditional antibiotics, this drug shows excellent resistance to SA bacteria in the laboratory where it has produced a series of low bacterial resistance potentials, and can be used to prevent and treat MRSA infection. The company has been listed on the Alternative Investment Market (AIM), a sub-market of London Stock Exchange (LSE), with a market value of 19 million pounds.
Enquire for more information about our services, and how we can help solve challenges for your organizationContact Us